This website uses cookies to ensure you get the best experience on our website. Privacy Policy
UroToday UroToday
  • Contact
  • Login
  • Sign Up Free
  • Transformative Evidence
    • mCRPC
      • The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
      • PROfound
      • VISION Trial
    • mHSPC
      • ARASENS Trial
    • nmCRPC
      • ARAMIS Trial
    • PSMA PET Imaging
      • CONDOR Trial
      • OSPREY Trial
    • Bladder Cancer
      • Bladder Cancer Detection
  • Trials in Progress
    • Trials in Progress
      • ECLIPSE Trial
      • Oral EPI-7386
      • SPLASH Trial
    • Right Side
      • PCCTC
        • DORA
        • IRONMAN
        • PROMISE
  • Centers of Excellence
    • Urologic Oncology
      • Left Group
        • Health Policy
          • Health Policy
            Ruchika Talwar, MD
        • Bladder Cancer
          • Bladder Cancer
            Ashish Kamat, MD
          • Advanced Bladder Cancer
            Petros Grivas, MD
        • Kidney Cancer
          • Advanced Kidney Cancer
            Pedro Barata, MD, MSc
          • Kidney Cancer Today
            Sumanta (Monty) Kumar Pal, MD
            Jaime Landman, MD
      • Prostate Cancer
        • Advanced Prostate Cancer
          Alicia Morgans, MD, MPH
        • CRPC with Bone Metastases
          Rana R. McKay, MD
        • Imaging Center
          Phillip Koo, MD
        • Localized Prostate Cancer
          Matthew R. Cooperberg, MD, MPH
        • mHSPC
          Alicia Morgans, MD, MPH
        • nmCRPC
          Alicia Morgans, MD, MPH
        • PSMA-Targeted Therapy
      • Disparities: Social Determinants of Health
        • Disparities: Social Determinants of Health
          Samuel L. Washington III, MD, MAS
      • Translational Prostate Cancer
        • Translational Science in Prostate Cancer
          Andrea Miyahira, Ph.D
        • Women in Science
          Andrea Miyahira, Ph.D
      • Upper Tract Urothelial Carcinoma
        • Upper Tract Urothelial Carcinoma
          Sam S. Chang, MD, MBA
      • TESTICULAR, PENILE & RARE GU MALIGNANCIES
        • Testicular, Penile, and Rare GU Malignancies
    • Pelvic Health & Reconstruction
      • Bladder Health
        Diane K. Newman, DNP, ANP-BC, FAAN
      • Pelvic Health
        Diane K. Newman, DNP, ANP-BC, FAAN
      • Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
        Stephen R. Kraus, MD
      • Urologic Catheters (Includes CAUTI)
        Diane K. Newman, DNP, ANP-BC, FAAN
      • Suprapubic Catheter
        Diane K. Newman, DNP FAAN BCB-PMD
  • Videos
    • Exclusives
      • Conferences
      • Exclusive Collaborations
      • Independent Education
      • Covid-19
      • The Prostate Cancer Foundation
    • Urologic Oncology
      • Prostate Cancer
      • Bladder Cancer
      • Kidney Cancer
      • Upper Tract Urothelial Tumors
      • Pelvic Health & Reconstruction
      • Endourology
      • Testicular Cancer
      • Health Policy in Urological Diseases
      • Disparities: Social Determinants of Health
  • Clinical Trials
    • From the Editor
      • Search Clinical Trials
  • Articles
    • Urology (benign and malignant)
      • Urologic Oncology
      • Men's Health
      • Endourology & Stones
      • Pediatric Urology
      • COVID-19 and Genitourinary Cancers
    • Pelvic Health
      • Pelvic Health & Reconstruction
  • Conference Coverage
    • Recent Conferences
      • ASCO 2023
      • AUA 2023
      • ASCO GU 2023
      • EAU 2023
    • All Conferences
      • View All
  • PCF
  1. UroToday Home
  2. Recent Abstracts
  3. Urologic Oncology
  4. Bladder Cancer

Conferences

Recent Abstracts
GU Cancers Symposium 2014 - Novel long noncoding RNA-dependent mechanisms of androgen receptor-regulated gene activation - Session Highlights January 30, 2014
GU Cancers Symposium 2014 - Unleashing the power of the immune system through combination therapy - Session Highlights January 30, 2014
GU Cancers Symposium 2014 - Dissecting the biology of the androgen receptor pathway - Session Highlights January 30, 2014
GU Cancers Symposium 2014 - Enzalutamide in men with chemotherapy-naive metastatic prostate cancer (mCRPC): Results of phase III PREVAIL study - Session Highlights January 30, 2014
Myriad's Prolaris® test significantly modifies treatment decisions for patients with prostate cancer January 29, 2014
Symposium highlights latest research advances in GU cancers January 28, 2014
GU Cancers Symposium 2014 - Premature termination of genitourinary cancer clinical trials - Slide Presentation January 28, 2014
GU Cancers Symposium 2014 - Impact of angiotensin system inhibitors on outcomes in patients with metastatic renal cell carcinoma (mRCC): Results from a pooled clinical trials database - Slide Presentation January 28, 2014
GU Cancers Symposium 2014 - Ten- and 15-year prostate cancer-specific survival in patients with nonmetastatic high-risk prostate cancer randomized to lifelong hormone treatment alone or combined with radiotherapy (SPCG VII) - Slide Presentation January 28, 2014
GU Cancers Symposium 2014 - Enzalutamide decreases risk of death and delays progression in phase III trial of men with metastatic prostate cancer - Slide Presentation January 28, 2014
GU Cancers Symposium 2014 - Enzalutamide in men with chemotherapy-naïve metastatic prostate cancer (mCRPC): Results of phase 3 PREVAIL study - Abstract January 25, 2014
Myriad Genetics to present five clinical studies at 2014 ASCO GU Cancer Symposium January 23, 2014
Embargoed presscast on January 28 to feature key research advances in genitourinary cancers, embargoed press release now available January 23, 2014
SUO 2013 - Session Highlights (Best Abstract Presentation): Experience with active surveillance (AS) in patients with renal mass > 4cm: Assessment of growth kinetics and outcomes December 10, 2013
SUO 2013 - Session Highlights: Evaluation of surveillance guidelines for renal cell carcinoma following partial nephrectomy December 10, 2013
SUO 2013 - Session Highlights: Targeted magnetic resonance imaging/ultrasound fusion biopsy significantly outperforms random 12-core biopsy for prediction of total prostate cancer tumor volume December 10, 2013
SUO 2013 - Session Highlights: NEUACT, a phase 2 randomized, open-label trial of DN24-02 in patients with surgically resected HER2+ urothelial cancer (UC): Updated analysis of product parameters, HER2 expression and safety December 9, 2013
SUO 2013 - Session Highlights: The influence of race on RCC incidence and survival December 9, 2013
SUO 2013 - Session Highlights: Comparative effectiveness research studies of robotic vs. open prostatectomy December 9, 2013
SUO 2013 - Session Highlights: Multicenter retrospective experience in the surgical management of isolated nodal recurrences post-nephrectomy in patients with renal cell carcinoma December 9, 2013
Page 480 of 522
  • Start
  • Prev
  • 475
  • 476
  • 477
  • 478
  • 479
  • 480
  • 481
  • 482
  • 483
  • 484
  • Next
  • End
  • About UroToday
  • Journals
  • Calendar
  • Editorial and Advertising Guidelines
  • Editors and Contributors
  • FAQs
  • Privacy Policy
  • Terms of Use
Follow UroToday

COPYRIGHT © 2002 - 2023 DIGITAL SCIENCE PRESS, LLC

Login

Login to update email address, newsletter preferences and use bookmarks.

  • Forgot Password?
  • Sign Up Free